Natixis Advisors LLC Purchases 431 Shares of Insmed Incorporated (NASDAQ:INSM)

Natixis Advisors LLC increased its holdings in Insmed Incorporated (NASDAQ:INSM) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,325 shares of the biopharmaceutical company’s stock after acquiring an additional 431 shares during the period. Natixis Advisors LLC’s holdings in Insmed were worth $1,472,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Steward Partners Investment Advisory LLC grew its stake in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC grew its position in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period. Spire Wealth Management purchased a new stake in Insmed during the fourth quarter worth about $47,000. Smartleaf Asset Management LLC increased its holdings in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in shares of Insmed in the 4th quarter worth approximately $86,000.

Insmed Trading Down 0.7 %

Shares of INSM stock opened at $79.38 on Tuesday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $14.37 billion, a P/E ratio of -14.20 and a beta of 1.28. The business has a 50-day moving average price of $77.64 and a two-hundred day moving average price of $73.84. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday, February 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. Guggenheim restated a “buy” rating and issued a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. Truist Financial upped their price target on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, Bank of America raised their price objective on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $27,079,091.58. The trade was a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the sale, the insider now owns 102,766 shares of the company’s stock, valued at $6,773,307.06. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 550,957 shares of company stock valued at $42,992,528. Insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.